Group 1: Company Performance - The company reported a slight decline in revenue of 0.27% year-on-year to 615 million yuan for the first half of 2025, while net profit increased by 11.96% to 70.856 million yuan, raising concerns about the sustainability of growth due to the revenue drop [2] - The company's current ratio is 0.91, indicating weak short-term debt repayment capability [2] Group 2: Stock Price Movement - The stock price fluctuated between 0.72 and 0.81 HKD recently, closing at 0.77 HKD on February 13, 2026, which is slightly below the 5-day and 10-day moving averages, indicating short-term downward pressure [3] - The MACD histogram, although positive, is narrowing, suggesting a decrease in upward momentum [3] Group 3: Industry Policy and Market Position - The water utility industry relies on capacity expansion or water price adjustments for profit growth, with the company's sewage and tap water business accounting for over 99% of its revenue [4] - Recently, the company has not announced any significant project launches or price adjustments, while competitors have disclosed multiple ongoing project developments, potentially diverting market attention [4]

Core Insights - Boston Scientific reported Q4 2025 revenue of $5.286 billion, a 15.9% year-over-year increase, exceeding market expectations of $5.280 billion [27][32] - The electrophysiology segment, which was highly anticipated, generated $890 million in sales, falling short of the market expectation of $933 million, leading to a stock price drop of over 17% [28][19] - The company's overall performance was strong, but the market reacted negatively due to concerns over the sustainability of growth driven by a single segment [19][48] Financial Performance - Q4 2025 revenue: $5.286 billion, up 15.9% YoY [32] - GAAP net profit: $672 million, up 18.7%, with earnings per share of $0.45 [32] - Adjusted EPS: $0.80, exceeding the company's guidance of $0.77-$0.79 [32] - Full-year revenue surpassed $20 billion for the first time, with a 19.9% YoY increase [33] Segment Performance - Cardiovascular segment revenue: $3.477 billion, up 18.2%, the strongest performing segment [32] - Electrophysiology segment growth was 35% in Q4, but analysts expressed concerns over the sustainability of this growth [44][39] - The Watchman device, another flagship product, reported $535 million in revenue, missing expectations by $4 million, indicating potential market saturation [45][44] Market Dynamics - The electrophysiology segment is critical to Boston Scientific's growth narrative, with the PFA technology previously showing explosive growth [37][39] - Competition is intensifying with the entry of Medtronic's PulseSelect and Johnson & Johnson's Varipulse, which may erode Boston Scientific's market share [41][43] - The U.S. market for PFA technology is experiencing a transition phase, which may limit future growth as initial conversions to PFA have been completed [39] Future Outlook - The company anticipates organic revenue growth of 10-11% for 2026, a significant slowdown from 15.8% in 2025 [49][48] - Management remains confident in maintaining market leadership in electrophysiology, with plans for product innovation and expansion into new indications [54] - International markets, particularly in China and Japan, present significant growth opportunities as they are still in early stages of PFA technology adoption [54]

Core Viewpoint - Morgan Stanley believes that the positive fundamentals of the optical module industry have largely been reflected in stock prices after several months of significant increases, leading to rating adjustments for multiple related stocks [1][2]. Group 1: Market Sentiment and Stock Performance - Morgan Stanley suggests that investors should take profits during periods of high market sentiment, as the positive fundamentals are widely recognized and reflected in stock prices [2]. - Since April, stock price increases have been substantial: New Yisheng up 460%, Zhongji Xuchuang up 312%, Tianfu Communication up 269%, and Huagong Technology up 62% [4]. Group 2: Rating Adjustments and Valuation Concerns - Morgan Stanley has made significant rating adjustments, notably downgrading New Yisheng to "Underweight," citing a potential slowdown in growth after a 338% year-on-year performance increase in Q2 2025 [3][10]. - The firm warns that the current valuations of New Yisheng and Tianfu Communication have exceeded historical averages, indicating that the positive fundamentals may have already been partially digested [7]. - The forward P/E ratio for Zhongji Xuchuang has risen from 14x to 24x, while New Yisheng's has increased from 8x to 20x since the beginning of 2025 [7]. Group 3: Future Growth Catalysts - Morgan Stanley views the rapid rollout of 1.6T products as a potential catalyst for growth in the second half of 2025 and 2026, despite delays in the GB300's launch affecting the timeline for 1.6T module shipments [13]. - The demand for 800G modules is expected to remain strong, which will help offset pricing and sales pressures on lower-end optical modules [13].